PRNewsWire
19 Dec 2025, 12:45 UTC · 39w ago
Verdict
Headline leans bullish. We score FOLD +0.90 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
BioMarin has entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction valued at approximately $4.8 billion.
More positive than 99% of claims this week
The acquisition is expected to be accretive to BioMarin's Non-GAAP Diluted EPS within the first 12 months post-close and substantially accretive starting in 2027.
Continue reading
5 related stories
More positive than 93% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
BioMarin will add Galafold and Pombiliti + Opfolda to its portfolio, which generated $599 million in revenue over the past four quarters.
More positive than 76% of claims this week
The deal includes the U.S. rights to DMX-200, a first-in-class investigational treatment for FSGS currently in Phase 3 development.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 93% of ticker scores this week
The company is being acquired at a significant premium (33% to last close) in an all-cash transaction.
More positive than 83% of ticker scores this week
The acquisition of Amicus is expected to accelerate revenue growth and be accretive to non-GAAP diluted EPS.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
1h ago
+33.1%
Price agrees with the score
$14.49 vs $10.89 close before publication (Dec 18) · not market-adjusted
FOLD chart →
